SAGE Therapeutics Inc Expected to Post FY2018 Earnings of ($7.45) Per Share (SAGE)

SAGE Therapeutics Inc (NASDAQ:SAGE) – Equities researchers at SunTrust Banks lifted their FY2018 earnings per share estimates for shares of SAGE Therapeutics in a note issued to investors on Tuesday, November 6th. SunTrust Banks analyst E. Nash now expects that the biopharmaceutical company will post earnings per share of ($7.45) for the year, up from their previous forecast of ($7.55). SunTrust Banks also issued estimates for SAGE Therapeutics’ Q4 2018 earnings at ($2.76) EPS, Q1 2019 earnings at ($2.87) EPS, Q2 2019 earnings at ($2.88) EPS, Q3 2019 earnings at ($2.88) EPS, Q4 2019 earnings at ($2.83) EPS, FY2019 earnings at ($11.46) EPS, FY2020 earnings at ($8.60) EPS, FY2021 earnings at ($5.36) EPS and FY2022 earnings at $1.45 EPS.

SAGE Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($2.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.41) by ($0.22). During the same quarter in the previous year, the company posted ($1.97) earnings per share.

Other research analysts also recently issued research reports about the company. Piper Jaffray Companies assumed coverage on SAGE Therapeutics in a research note on Monday, August 6th. They issued an “overweight” rating and a $206.00 price objective for the company. BidaskClub downgraded SAGE Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, July 27th. Canaccord Genuity set a $220.00 price objective on SAGE Therapeutics and gave the company a “buy” rating in a research note on Wednesday, August 8th. LADENBURG THALM/SH SH set a $235.00 price target on SAGE Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, October 31st. Finally, Oppenheimer set a $170.00 price target on SAGE Therapeutics and gave the stock a “buy” rating in a research note on Monday, October 29th. One investment analyst has rated the stock with a sell rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. SAGE Therapeutics has an average rating of “Buy” and a consensus price target of $204.06.

Shares of NASDAQ:SAGE opened at $132.83 on Friday. SAGE Therapeutics has a 1 year low of $83.00 and a 1 year high of $195.97.

Several hedge funds have recently bought and sold shares of the company. FMR LLC grew its stake in shares of SAGE Therapeutics by 1.6% during the 2nd quarter. FMR LLC now owns 6,977,378 shares of the biopharmaceutical company’s stock worth $1,092,169,000 after acquiring an additional 110,687 shares during the period. OppenheimerFunds Inc. lifted its holdings in SAGE Therapeutics by 2.2% during the 2nd quarter. OppenheimerFunds Inc. now owns 1,598,167 shares of the biopharmaceutical company’s stock worth $250,162,000 after purchasing an additional 34,389 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in SAGE Therapeutics by 7.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,564,548 shares of the biopharmaceutical company’s stock worth $244,898,000 after purchasing an additional 110,134 shares in the last quarter. BB Biotech AG lifted its holdings in SAGE Therapeutics by 6.9% during the 2nd quarter. BB Biotech AG now owns 1,071,373 shares of the biopharmaceutical company’s stock worth $167,702,000 after purchasing an additional 68,934 shares in the last quarter. Finally, Jennison Associates LLC lifted its holdings in SAGE Therapeutics by 0.6% during the 3rd quarter. Jennison Associates LLC now owns 810,224 shares of the biopharmaceutical company’s stock worth $114,444,000 after purchasing an additional 4,863 shares in the last quarter.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Read More: Investing in Growth Stocks

Earnings History and Estimates for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply